Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy

Junshik Hong, Sanghui Park, Jinny Park, Hyung Sun Kim, Kyung Hee Kim, Jeong Yeal Ahn, Min Young Rim, Minkyu Jung, Sun Jin Sym, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

The relationship between histopathologic characteristics and treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy needs re-evaluation. Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) were evaluated with respect to clinical characteristics, treatment efficacy, and survival. Immunohistochemistry of bcl-2, CD10, bcl-6, and MUM-1 was performed and patients were sub-classified as germinal center B-cell-like (GCB) or non-GCB type according to the Hans algorithm. There was no significant difference in overall survival (OS) between patients with GCB and those with non-GCB. Although there was no significant difference in OS between high-intermediate and high risk groups as classified by the s andard International Prognostic Index (IPI; p=0.50), all three groups with the revised IPI had a clear-cut separation for event-free survival and OS. The revised IPI better predicted survival than did the standard IPI in patients with DLBCL treated with R-CHOP. The Hans classification had no prognostic value.

Original languageEnglish
Pages (from-to)1904-1912
Number of pages9
JournalLeukemia and Lymphoma
Volume52
Issue number10
DOIs
StatePublished - Oct 2011

Keywords

  • Diffuse large B-cell lymphoma
  • immunochemotherapy
  • immunohistochemistry
  • prognosis
  • rituximab

Fingerprint

Dive into the research topics of 'Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy'. Together they form a unique fingerprint.

Cite this